- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefTM
- Patient Resources
There is a high prevalence of depression among patients with chronic kidney disease (CKD). This presentation will examine the clinical overlap between CKD and major depressive disorder (MDD) in symptomatology, behavioral and biological mechanisms, the impact of comorbid depression on CKD outcomes, and strategies for effective management of depression in CKD.
- Discuss the high prevalence of depression in patients with CKD.
- Discuss how overlap of symptomatology between MDD and CKD makes diagnosing depression in the setting of CKD challenging.
- Discuss the association of MDD with poor outcomes in CKD.
- Discuss potential risk factors and mechanism of MDD in CKD.
- Discuss the cycle between MDD and ESRD.
- Address challenges in MDD management considerations in CKD patients.
*Speakers are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.
Dr. Pinto received her bachelor’s in pharmacy from the Federal University on Ceara, Brazil in 2001. Dr. Pinto concluded her master and doctorate program in pharmacology and toxicology at the University of Kansas (2005 and 2007). Dr Pinto joined the University of Kansas Medical Center Kidney Institute in 2007 as a postdoctoral fellow, where she completed her fellowship in nephrology with emphasis in polycystic kidney disease translational research. Cibele Pinto has published in relevant peer reviewed journals in the areas of neuro and renal pharmacology such as Journal of Neurochemistry, American Journal of Renal Physiology and Kidney International. Dr. Cibele Pinto is currently a Senior Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Prior to joining Otsuka Laura attained a PhD in Pharmacology and Toxicology from the University of Kanas. Her doctoral work centered in the neuroscience space specifically on mechanisms of neurodegeneration and neurotoxicity. During this time Laura also served as an Adjunct Professor at Highlands Community College where she taught Human Anatomy and Physiology courses. After completion of graduate school Laura worked at a Contract Research Organization (CRO) where she managed their clinical pharmacology unit for seven years. Through these years she managed hundreds of program projects in Phases 1-2b across all therapeutic areas, i.e., oncology, neuroscience, medical devices, etc. Laura has been with Otsuka for five years now and her territories include the states of Kansas, Oklahoma and western sections of Missouri.
Online via NephU.orgNephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.May 2020 MRC2.CORP.X.04767
- Resource Center
- Patient Resources